These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 30845097)
1. Xyosted--a testosterone auto-injector for hypogonadism. Med Lett Drugs Ther; 2019 Mar; 61(1567):37-38. PubMed ID: 30845097 [No Abstract] [Full Text] [Related]
2. Jatenzo - an oral testosterone for hypogonadism. Med Lett Drugs Ther; 2021 Jun; 63(1627):103-104. PubMed ID: 34181633 [No Abstract] [Full Text] [Related]
3. Two new oral testosterone products for hypogonadism. Med Lett Drugs Ther; 2022 Oct; 64(1662):172-174. PubMed ID: 36383769 [No Abstract] [Full Text] [Related]
4. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. Gittelman M; Jaffe JS; Kaminetsky JC J Sex Med; 2019 Nov; 16(11):1741-1748. PubMed ID: 31551193 [TBL] [Abstract][Full Text] [Related]
5. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. Kaminetsky JC; McCullough A; Hwang K; Jaffe JS; Wang C; Swerdloff RS J Urol; 2019 Mar; 201(3):587-594. PubMed ID: 30296416 [TBL] [Abstract][Full Text] [Related]
7. Testosterone undecanoate in the treatment of male hypogonadism. Edelstein D; Basaria S Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374 [TBL] [Abstract][Full Text] [Related]
8. A new testosterone gel (fortesta) for hypogonadism. Med Lett Drugs Ther; 2011 Apr; 53(1362):29-30. PubMed ID: 21502933 [TBL] [Abstract][Full Text] [Related]
9. Testosterone administration in older men. Matsumoto AM Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401 [TBL] [Abstract][Full Text] [Related]
11. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. Kaminetsky JC; Moclair B; Hemani M; Sand M J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402 [TBL] [Abstract][Full Text] [Related]
12. Testosterone replacement therapy for older men. Wald M; Meacham RB; Ross LS; Niederberger CS J Androl; 2006; 27(2):126-32. PubMed ID: 16474018 [No Abstract] [Full Text] [Related]
14. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice. Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472 [TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Seftel A Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074 [TBL] [Abstract][Full Text] [Related]
17. Risks of testosterone-replacement therapy and recommendations for monitoring. Rhoden EL; Morgentaler A N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457 [No Abstract] [Full Text] [Related]
18. Testosterone replacement therapy: who to evaluate, what to use, how to follow, and who is at risk? Afiadata A; Ellsworth P Hosp Pract (1995); 2014 Dec; 42(5):69-82. PubMed ID: 25485919 [TBL] [Abstract][Full Text] [Related]
19. Novel Therapy for Male Hypogonadism. Carrasquillo R; Chu K; Ramasamy R Curr Urol Rep; 2018 Jun; 19(8):63. PubMed ID: 29886559 [TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy and cardiovascular events. Çatakoğlu AB; Kendirci M Turk Kardiyol Dern Ars; 2017 Oct; 45(7):664-672. PubMed ID: 28990951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]